CytoDyn (CYDY) Long-Term Debt Repayments (2012 - 2020)

CytoDyn (CYDY) posted Long-Term Debt Repayments of $460000.0 for Q2 2020, up 255655.56% on a QoQ basis from -$180.0 in Q2 2015.

CytoDyn (CYDY) Long-Term Debt Repayments (2012 - 2020) Analysis & Trends

CytoDyn's Long-Term Debt Repayments history runs 4 years deep, the most recent figure standing at $460000.0 for Q2 2020.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $460000.0 in Q2 2020, while the trailing twelve-month figure through May 2021 was $459820.0 (down 35.22% YoY) and the FY2021 annual result came in at $950000.0, down 56.52% from the prior year.
Long-Term Debt Repayments was $460000.0 for Q2 2020 at CytoDyn, up from -$180.0 in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $460000.0 in Q2 2020 and bottomed at $460000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Download Data